Ajay Samkaria/LinkedIn
May 22, 2026, 13:36
Ajay Samkaria։ A Compatible Crossmatch Does Not Always Mean Complete Safety
Ajay Samkaria, Product and Application Manager India at Diagast, shared a post on LinkedIn:
“Crossmatch protects the present transfusion.
Antibody screening protects the patient’s future.
A compatible crossmatch does not always mean complete transfusion safety.
Some clinically significant antibodies may still go undetected unless proper antibody screening is performed.
That’s why modern transfusion medicine is shifting from: ‘minimum compatibility’ to ‘future transfusion safety.’
Think Beyond Crossmatch.
Think Antibody Screening.
Think Patient Safety.”
Stay updated with Hemostasis Today.
-
Jul 8, 2026, 14:17Maha Othman: Advancing Thrombosis and Hemostasis Research at ISTH 2026
-
Jul 8, 2026, 14:07Zain Khalpey: Atrial Fibrillation as the Hidden Driver of Preventable Ischemic Stroke
-
Jul 8, 2026, 11:33Ifeanyichukwu Ifechidere: Haemophilia A and B – From First Diagnosis to the Era of Gene Therapy
-
Jul 8, 2026, 10:29Bringing Hemophilia Care Closer to Communities in Togo – WFH
-
Jul 8, 2026, 10:12Natasha Jolakoski: Completing Advanced Training in Thrombosis and Hemostasis
-
Jul 8, 2026, 09:58Rola Ghasoub: Early Intracranial Hemorrhage Remains the Main Barrier to Cure in Acute Promyelocytic Leukemia
-
Jul 8, 2026, 05:53Excellent PhD Defense by Roberta Cirsmaru on Gene Therapy for Hemophilia A – CRH French Reference Center for Hemophilia Lyon
-
Jul 8, 2026, 05:48Riccardo Menandro: How Lipid Nanoparticles Are Shaping the Future of Rare Disease and Hemophilia Treatment
-
Jul 8, 2026, 05:39Daniel Victor Ortigoza: New Evidence from ATLANTIS-4D-CT on Apixaban and Subclinical Valve Thrombosis